Merck & Co.'s big-selling cholesterol-fighter Zetia is at the end of its exclusive road. The $2.5 billion seller now faces its first generic competitor, which threatens not only its own revenue, but ...

Despite new US cholesterol guidelines and a clinical trial that tamped down hopes that Merck’s cholesterol drug Zetia could make a difference in the rare disease space, an analysis of prescription ...

Add Yahoo as a preferred source to see more of our stories on Google. By Bill Berkrot CHICAGO (Reuters) - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol ...

NEW ORLEANS, November 8, 2004 – Results from a new study showed that coadministration of ZETIA® (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density ...

WHITEHOUSE STATION -- Shares of Whitehouse Station-based Merck rose 2.15 percent yesterday after results of a clinical trial of its cholesterol drug Zetia were not as negative as some analysts had ...

Schering-Plough is looking to its cholesterol treatments Vytorin and Zetia to help boost earnings for the next several years as the drug maker develops new products, CEO Fred Hassan said.“It’s the ...

CHICAGO - Leading doctors urged a return to older, tried-and-true treatments for high cholesterol after hearing full results Sunday of a failed trial of Vytorin. Millions of Americans already take the ...

(Reuters) - Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs.

Q. I have hereditary high cholesterol and Type 1 diabetes. My endocrinologist was pushing me to take a statin. Because many people I know have side effects such as muscle pain, I resisted. Finally, he ...

NEWARK (CN) - In a shareholder's class action that neatly summarizes complaints about Schering-Plough Corp.'s sales of its cholesterol drugs Zetia and Vytorin, the Arkansas Teacher Retirement System ...

After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an ...

CHICAGO (Reuters) - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients ...